Clincosm LogoSign in Get a demo

A Study in Healthy Men to Test How BI 1358894 is Taken up and Handled by the Body

Sponsor
Boehringer Ingelheim (Industry)
Overall Status
Completed
CT.gov ID
NCT04567316
Collaborator
(none)
15
Enrollment
1
Location
2
Arms
2.7
Actual Duration (Months)
5.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main objective of this trial is to investigate the basic pharmacokinetics of BI 1358894 and its metabolites, total radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of [14C] BI 1358894 in Part 1 and to investigate the pharmacokinetics of BI 1358894 and its metabolite(s) following multiple-dose treatment over 21 days with non- radiolabelled compound of BI 1358894 in Part 2.

Condition or Disease Intervention/Treatment Phase
  • Drug: [14C]-radiolabelled BI 1358894
  • Drug: BI 1358894
 Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
15 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I, Open-label Trial to Investigate Metabolism and Pharmacokinetics of a Single Dose of [14C] BI 1358894 Administered as Oral Solution (Part 1) and Multiple Doses of BI 1358894 Administered as Film-coated Tablets (Part 2) in Healthy Male Volunteers
Actual Study Start Date :
Oct 19, 2020
Actual Primary Completion Date :
Jan 10, 2021
Actual Study Completion Date :
Jan 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: [14C]-radiolabelled BI 1358894

[14C]-radiolabelled BI 1358894 (part 1)

Drug: [14C]-radiolabelled BI 1358894
Part 1
Experimental: BI 1358894

BI 1358894 (part 2)

Drug: BI 1358894
Part 2

Outcome Measures

Primary Outcome Measures

  1. Mass balance recoveries of [14C] BI 1358894 total radioactivity in urine and faeces after single oral dose [Up to Day 50]

  2. Amount of radioactivity excreted as a percentage of the administered dose (fe0-t2) for urine and faeces [Up to Day 50]

Secondary Outcome Measures

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) [Up to Day 50]

    part 1

  2. Maximum measured concentration of the analyte in plasma (Cmax) [Up to Day 50]

    part 1

  3. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 (AUC0-24) [Up to Day 62]

    part 2

  4. Maximum measured concentration of the analyte in plasma (Cmax) [Up to Day 62]

    part 2

  5. Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) [Up to Day 62]

    part 2

  6. Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss) [Up to Day 62]

    part 2

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests

  • Age of 18 to 65 years (inclusive)

  • BMI of 18.5 to 29.9 kg/m2 (inclusive)

  • Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation

  • Male subjects who meet any of the following criteria from screening until 90 days after trial completion:

  • Use of adequate contraception of the female partner, e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives, intrauterine device that started at least two months prior to first study drug administration or barrier method (e.g. diaphragm with spermicide) or,

  • Sexually abstinent or,

  • A vasectomy performed at least 1 year prior to screening (with medical assessment of the surgical success) or,

  • Surgically sterilised female partner (including hysterectomy, bilateral tubal occlusion, or bilateral oophorectomy) or,

  • Postmenopausal female partner, defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with levels of follicle-stimulating Hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator

  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 40 to 100 bpm

  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance

  • C-reactive protein (CRP) > upper limit of normal (ULN), liver or kidney parameter above ULN

  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator

  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)

  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders

  • For Part 1 only:

  • Participation in another absorption, distribution, metabolism, and excretion (ADME) pharmacokinetics study with a radiation burden of >0.1 millisievert (mSv) in the period of 1 year prior to screening

  • Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of thorax and bony skeleton (excluding spinal column)) in the period of 1 year prior to screening

  • Irregular defecation pattern (less than a mean of one bowel movement every 1 or 2 days)

In addition, the following Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific exclusion criterion apply:

  • A positive test indicating an ongoing infection with SARS-CoV-2 and clinical symptoms suggestive of the disease

  • Further exclusion criteria apply

Contacts and Locations

Locations

Site City State Country Postal Code
1 PRA Health Sciences Onderzoekscentrum Martini Groningen Netherlands 9728 NZ

Sponsors and Collaborators

  • Boehringer Ingelheim

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT04567316
Other Study ID Numbers:
  • 1402-0015
  • 2020-002054-25
First Posted:
Sep 28, 2020
Last Update Posted:
Jan 13, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes

Study Results

No Results Posted as of Jan 13, 2021